A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Clinical trial NCT03069378 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03069378
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-03
- Primary completion
- 2025-07-22
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.